Compare ADMA Biologics Inc (ADMA) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Kinross Gold Corporation — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Kinross Gold Corporation trades at $23.07 (market cap $28.53B). The key difference: Kinross Gold Corporation is far larger — about 13.4× ADMA Biologics Inc's market cap, and Kinross Gold Corporation pays a 0.61% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KGC | |
|---|---|---|
Market Cap | $2.13B | $28.53B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $38.06 |
52-Week Low | $7.60 | $15.19 |
Enterprise Value | $2.20B | $27.08B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Kinross Gold (KGC) trades at $23.87, down 3.4% over 24 hours amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Recent quarters show consistent earnings beats, with Q2 2026 results expected on July 29. Analyst consensus remains bullish with a $35.33 price target representing 48% upside potential.
KGC presents a compelling value opportunity with attractive valuation ratios (P/E 10.52, EV/EBITDA 5.46) and robust profitability (35.99% net margin). Key risks include gold price volatility and rising operational costs. The company's strong cash flow generation and growth projects support long-term upside, though technical indicators suggest near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
